Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 617282, 6 pages
http://dx.doi.org/10.1155/2015/617282
Research Article

Elevated Serum Levels of Soluble CD30 in Ankylosing Spondylitis Patients and Its Association with Disease Severity-Related Parameters

1Department of Rheumatology and Immunology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China
2Department of Stomatology, Union Hospital, Huazhong University of Science and Technology, Wuhan 430022, China

Received 12 October 2014; Revised 14 December 2014; Accepted 28 December 2014

Academic Editor: James C. C. Wei

Copyright © 2015 Rongfen Gao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. F. Shamji, M. Bafaquh, and E. Tsai, “The pathogenesis of ankylosing spondylitis,” Neurosurgical Focus, vol. 24, no. 1, article E3, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Wang, Q. Liao, Y. Hu, and D. Zhong, “T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis,” Experimental and Therapeutic Medicine, vol. 9, no. 1, pp. 250–256, 2015. View at Publisher · View at Google Scholar
  3. J. A. Smith, “Update on ankylosing spondylitis: current concepts in pathogenesis,” Current Allergy and Asthma Reports, vol. 15, no. 1, article 489, 2015. View at Publisher · View at Google Scholar
  4. T. Haque, T. Chaggar, J. Schafers, C. Atkinson, K. A. McAulay, and D. H. Crawford, “Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases,” Journal of Medical Virology, vol. 83, no. 2, pp. 311–316, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Mielczarek-Palacz, J. Sikora, Z. Kondera-Anasz, and G. Hauza, “Imbalance in serum soluble CD30/CD30L and CD40/CD40L systems are associated with ovarian tumors,” Human Immunology, vol. 74, no. 1, pp. 70–74, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Tinazzi, A. Barbieri, A. Rigo et al., “In rheumatoid arthritis soluble CD30 ligand is present at high levels and induces apoptosis of CD30+ T cells,” Immunology Letters, vol. 161, no. 2, pp. 236–240, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Michai, H. Goto, S. Hattori et al., “Soluble CD30: a possible serum tumor marker for primary effusion lymphoma,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 10, pp. 4939–4941, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. H. P. Hansen, S. Dietrich, T. Kisseleva et al., “CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme,” The Journal of Immunology, vol. 165, no. 12, pp. 6703–6709, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. L. L. F. G. Valke, B. van Cranenbroek, L. B. Hilbrands, and I. Joosten, “Soluble CD30 does not predict late acute rejection or safe tapering of immunosuppression in renal transplantation,” Transplant Immunology, vol. 32, no. 1, pp. 18–22, 2015. View at Publisher · View at Google Scholar
  10. H. Ulusoy, A. Kamanli, N. Ilhan et al., “Serum levels of soluble CD26 and CD30 and their clinical significance in patients with rheumatoid arthritis,” Rheumatology International, vol. 32, no. 12, pp. 3857–3862, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Gerli, O. Bistoni, C. Lunardi et al., “Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy,” Rheumatology, vol. 38, no. 12, pp. 1282–1284, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Dong, S. Hu, F. Chen et al., “Increased expression of ganglioside GM1 in peripheral CD4+ T cells correlates soluble form of CD30 in systemic lupus erythematosus patients,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 569053, 8 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Ciferská, P. Horák, Z. Heřmanová et al., “The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value,” Clinical Rheumatology, vol. 26, no. 5, pp. 723–728, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Ihn, N. Yazawa, M. Kubo et al., “Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease,” Journal of Rheumatology, vol. 27, no. 3, pp. 698–702, 2000. View at Google Scholar · View at Scopus
  15. P. Oktayoglu, S. Em, M. Tahtasiz et al., “Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life,” Rheumatology International, vol. 33, no. 5, pp. 1327–1331, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Akkoc, A. G. Karatepe, S. Akar, Y. Kirazli, and N. Akkoc, “A Turkish version of the bath ankylosing spondylitis disease activity index: reliability and validity,” Rheumatology International, vol. 25, no. 4, pp. 280–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Zhang, K. Yu, R. Guo et al., “Ankylosing spondylitis: correlations between clinical and MRI indices of sacroiliitis activity,” Clinical Radiology, vol. 70, no. 1, pp. 62–66, 2015. View at Publisher · View at Google Scholar
  18. A. Calin, S. Garrett, H. Whitelock et al., “A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index,” The Journal of Rheumatology, vol. 21, no. 12, pp. 2281–2285, 1994. View at Google Scholar · View at Scopus
  19. M. D. Reed, S. Dharmage, A. Boers, B. J. Martin, R. R. Buchanan, and L. Schachna, “Ankylosing spondylitis: an Australian experience,” Internal Medicine Journal, vol. 38, no. 5, pp. 321–327, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. Q. Wu, J. Zhang, J. Shi et al., “Increased bone marrow (BM) plasma level of soluble CD30 and correlations with BM plasma level of interferon (IFN)-γ, CD4/CD8 T-cell ratio and disease aeverity in aplastic anemia,” PLoS ONE, vol. 9, no. 11, Article ID e110787, 2014. View at Publisher · View at Google Scholar
  21. M. Østensen, F. Förger, J. L. Nelson, A. Schuhmacher, G. Hebisch, and P. M. Villiger, “Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum,” Annals of the Rheumatic Diseases, vol. 64, no. 6, pp. 839–844, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Frezzolini, M. Paradisi, M. Ruffelli, S. Cadoni, and O. de Pità, “Soluble CD30 in pediatric patients with atopic dermatitis,” Allergy, vol. 52, no. 1, pp. 106–109, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. S. T. Remes, W. Delezuch, K. Pulkki, J. Pekkanen, M. Korppi, and I. H. Matinlauri, “Association of serum-soluble CD26 and CD30 levels with asthma, lung function and bronchial hyper-responsiveness at school age,” Acta Paediatrica, International Journal of Paediatrics, vol. 100, no. 9, pp. e106–e111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Chrul and E. Polakowska, “Age-dependent changes of serum soluble CD30 concentration in children,” Pediatric Transplantation, vol. 15, no. 5, pp. 515–518, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Krampera, F. Vinante, L. Tavecchia et al., “Progressive polarization towards a T helper/cytotoxic type-1 cytokine pattern during age-dependent maturation of the immune response inversely correlates with CD30 cell expression and serum concentration,” Clinical and Experimental Immunology, vol. 117, no. 2, pp. 291–297, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. J.-Y. Chen, L.-S. Fu, J.-J. Chu, H.-C. Chen, and C.-S. Chi, “Plasma soluble CD30 level correlates negatively with age in children,” Journal of Microbiology, Immunology and Infection, vol. 40, no. 2, pp. 168–172, 2007. View at Google Scholar · View at Scopus
  27. F. Caligaris-Cappio, M. T. Bertero, M. Converso et al., “Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity,” Clinical and Experimental Rheumatology, vol. 13, no. 3, pp. 339–343, 1995. View at Google Scholar · View at Scopus
  28. S. Romagnani, G. del Prete, E. Maggi, M. Chilosi, F. Caligaris-Cappio, and G. Pizzolo, “CD30 and type 2 T helper (Th2) responses,” Journal of Leukocyte Biology, vol. 57, no. 5, pp. 726–730, 1995. View at Google Scholar
  29. P. Pellegrini, A. M. Berghella, I. Contasta, and D. Adorno, “CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response,” Transplant Immunology, vol. 12, no. 1, pp. 49–61, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Pellegrini, R. Totaro, I. Contasta, A. M. Berghella, A. Carolei, and D. Adorno, “CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance: the role of IFNβ-1a in the treatment of multiple sclerosis,” NeuroImmunoModulation, vol. 12, no. 4, pp. 220–234, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Contasta, A. M. Berghella, P. Pellegrini, and D. Adorno, “Passage from normal mucosa to adenoma and colon cancer: Alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions,” Cancer Biotherapy and Radiopharmaceuticals, vol. 18, no. 4, pp. 549–557, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Mahmoudi, M. Hedayat, A. Aghamohammadi, and N. Rezaei, “Soluble CD26 and CD30 levels in patients with common variable immunodeficiency,” Journal of Investigational Allergology and Clinical Immunology, vol. 23, no. 2, pp. 120–124, 2013. View at Google Scholar · View at Scopus
  33. J. Ruof and G. Stucki, “Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review,” Journal of Rheumatology, vol. 26, no. 4, pp. 966–970, 1999. View at Google Scholar · View at Scopus
  34. A. Spoorenberg, D. van der Heijde, E. de Klerk et al., “Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis,” Journal of Rheumatology, vol. 26, no. 4, pp. 980–984, 1999. View at Google Scholar · View at Scopus